FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156885603> ?p ?o ?g. }

• W2156885603 endingPage "537" @default.
• W2156885603 startingPage "531" @default.
• W2156885603 abstract "Background The Thai phase 3 HIV vaccine trial RV 144 showed modest efficacy of a vaccine against HIV acquisition. Baseline variables of age, sex, marital status, and risk did not modify vaccine efficacy. We did a post-hoc analysis of the trial's data to investigate behavioural risk and efficacy every 6 months after vaccination. Methods RV 144 was a randomised, multicentre, double-blind, placebo-controlled efficacy trial testing the combination of the HIV vaccines ALVAC-HIV (vCP1521) and AIDSVAX B/E to prevent HIV infection or reduce setpoint viral load. Male and female volunteers aged 18–30 years were recruited from the community. In this post-hoc analysis of the modified intention-to-treat population (16 395 participants), HIV risk behaviour was assessed with a self-administered questionnaire at the time of initial vaccination in the trial and every 6 months thereafter for 3 years. We classified participants' behaviour as low, medium, or high risk. Both the acquisition endpoint and the early viral-load endpoint were examined for interactions with risk status over time and temporal effects after vaccination. Multiple proportional hazards regression models with treatment and time-varying risk covariates were analysed. Findings Risk of acquisition of HIV was low in each risk group, but 9187 (58·2%) participants reported higher-risk behaviour at least once during the study. Participants classified as high or increasing risk at least once during follow-up were compared with those who maintained low-risk or medium-risk behaviour as a time-varying covariate, and the interaction of risk status and acquisition efficacy was significant (p=0·01), with greater benefit in low-risk individuals. Vaccine efficacy seemed to peak early—cumulative vaccine efficacy was estimated to be 60·5% (95% CI 22–80) through the 12 months after initial vaccination—and declined quickly. Vaccination did not seem to affect viral load in either early or late infections. Interpretation Future HIV vaccine trials should recognise potential interactions between challenge intensity and risk heterogeneity in both population and treatment effects. The regimen tested in the RV 144 phase 3 trial might benefit from extended immunisation schedules. Funding US Army Medical Research and Materiel Command and Division of AIDS, National Institute of Allergy and Infectious Disease, National Institutes of Health. The Thai phase 3 HIV vaccine trial RV 144 showed modest efficacy of a vaccine against HIV acquisition. Baseline variables of age, sex, marital status, and risk did not modify vaccine efficacy. We did a post-hoc analysis of the trial's data to investigate behavioural risk and efficacy every 6 months after vaccination. RV 144 was a randomised, multicentre, double-blind, placebo-controlled efficacy trial testing the combination of the HIV vaccines ALVAC-HIV (vCP1521) and AIDSVAX B/E to prevent HIV infection or reduce setpoint viral load. Male and female volunteers aged 18–30 years were recruited from the community. In this post-hoc analysis of the modified intention-to-treat population (16 395 participants), HIV risk behaviour was assessed with a self-administered questionnaire at the time of initial vaccination in the trial and every 6 months thereafter for 3 years. We classified participants' behaviour as low, medium, or high risk. Both the acquisition endpoint and the early viral-load endpoint were examined for interactions with risk status over time and temporal effects after vaccination. Multiple proportional hazards regression models with treatment and time-varying risk covariates were analysed. Risk of acquisition of HIV was low in each risk group, but 9187 (58·2%) participants reported higher-risk behaviour at least once during the study. Participants classified as high or increasing risk at least once during follow-up were compared with those who maintained low-risk or medium-risk behaviour as a time-varying covariate, and the interaction of risk status and acquisition efficacy was significant (p=0·01), with greater benefit in low-risk individuals. Vaccine efficacy seemed to peak early—cumulative vaccine efficacy was estimated to be 60·5% (95% CI 22–80) through the 12 months after initial vaccination—and declined quickly. Vaccination did not seem to affect viral load in either early or late infections. Future HIV vaccine trials should recognise potential interactions between challenge intensity and risk heterogeneity in both population and treatment effects. The regimen tested in the RV 144 phase 3 trial might benefit from extended immunisation schedules." @default.
• W2156885603 created "2016-06-24" @default.
• W2156885603 creator A5001108158 @default.
• W2156885603 creator A5001119457 @default.
• W2156885603 creator A5002299399 @default.
• W2156885603 creator A5002675485 @default.
• W2156885603 creator A5005654192 @default.
• W2156885603 creator A5005840020 @default.
• W2156885603 creator A5005978177 @default.
• W2156885603 creator A5006743328 @default.
• W2156885603 creator A5036265394 @default.
• W2156885603 creator A5052819133 @default.
• W2156885603 creator A5053448144 @default.
• W2156885603 creator A5058440042 @default.
• W2156885603 creator A5062923881 @default.
• W2156885603 creator A5072696926 @default.
• W2156885603 creator A5076243921 @default.
• W2156885603 creator A5076820552 @default.
• W2156885603 creator A5081163351 @default.
• W2156885603 creator A5083488297 @default.
• W2156885603 creator A5085731242 @default.
• W2156885603 creator A5089514918 @default.
• W2156885603 date "2012-07-01" @default.
• W2156885603 modified "2023-10-09" @default.
• W2156885603 title "Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144" @default.
• W2156885603 cites W185366093 @default.
• W2156885603 cites W1893500657 @default.
• W2156885603 cites W1965175217 @default.
• W2156885603 cites W1976453734 @default.
• W2156885603 cites W1985666662 @default.
• W2156885603 cites W1992194744 @default.
• W2156885603 cites W1997519956 @default.
• W2156885603 cites W2006054189 @default.
• W2156885603 cites W2027489196 @default.
• W2156885603 cites W2038633253 @default.
• W2156885603 cites W2062263111 @default.
• W2156885603 cites W2080386250 @default.
• W2156885603 cites W2081790590 @default.
• W2156885603 cites W2087866505 @default.
• W2156885603 cites W2088400322 @default.
• W2156885603 cites W2094438164 @default.
• W2156885603 cites W2099311529 @default.
• W2156885603 cites W2104823480 @default.
• W2156885603 cites W2119835296 @default.
• W2156885603 cites W2138652626 @default.
• W2156885603 cites W2143421242 @default.
• W2156885603 cites W2146265568 @default.
• W2156885603 cites W2150249219 @default.
• W2156885603 cites W2152048324 @default.
• W2156885603 cites W2152640863 @default.
• W2156885603 doi "https://doi.org/10.1016/s1473-3099(12)70088-9" @default.
• W2156885603 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3530398" @default.
• W2156885603 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22652344" @default.
• W2156885603 hasPublicationYear "2012" @default.
• W2156885603 type Work @default.
• W2156885603 sameAs 2156885603 @default.
• W2156885603 citedByCount "187" @default.
• W2156885603 countsByYear W21568856032012 @default.
• W2156885603 countsByYear W21568856032013 @default.
• W2156885603 countsByYear W21568856032014 @default.
• W2156885603 countsByYear W21568856032015 @default.
• W2156885603 countsByYear W21568856032016 @default.
• W2156885603 countsByYear W21568856032017 @default.
• W2156885603 countsByYear W21568856032018 @default.
• W2156885603 countsByYear W21568856032019 @default.
• W2156885603 countsByYear W21568856032020 @default.
• W2156885603 countsByYear W21568856032021 @default.
• W2156885603 countsByYear W21568856032022 @default.
• W2156885603 countsByYear W21568856032023 @default.
• W2156885603 crossrefType "journal-article" @default.
• W2156885603 hasAuthorship W2156885603A5001108158 @default.
• W2156885603 hasAuthorship W2156885603A5001119457 @default.
• W2156885603 hasAuthorship W2156885603A5002299399 @default.
• W2156885603 hasAuthorship W2156885603A5002675485 @default.
• W2156885603 hasAuthorship W2156885603A5005654192 @default.
• W2156885603 hasAuthorship W2156885603A5005840020 @default.
• W2156885603 hasAuthorship W2156885603A5005978177 @default.
• W2156885603 hasAuthorship W2156885603A5006743328 @default.
• W2156885603 hasAuthorship W2156885603A5036265394 @default.
• W2156885603 hasAuthorship W2156885603A5052819133 @default.
• W2156885603 hasAuthorship W2156885603A5053448144 @default.
• W2156885603 hasAuthorship W2156885603A5058440042 @default.
• W2156885603 hasAuthorship W2156885603A5062923881 @default.
• W2156885603 hasAuthorship W2156885603A5072696926 @default.
• W2156885603 hasAuthorship W2156885603A5076243921 @default.
• W2156885603 hasAuthorship W2156885603A5076820552 @default.
• W2156885603 hasAuthorship W2156885603A5081163351 @default.
• W2156885603 hasAuthorship W2156885603A5083488297 @default.
• W2156885603 hasAuthorship W2156885603A5085731242 @default.
• W2156885603 hasAuthorship W2156885603A5089514918 @default.
• W2156885603 hasBestOaLocation W21568856032 @default.
• W2156885603 hasConcept C126322002 @default.
• W2156885603 hasConcept C142462285 @default.
• W2156885603 hasConcept C142724271 @default.
• W2156885603 hasConcept C203014093 @default.
• W2156885603 hasConcept C204787440 @default.
• W2156885603 hasConcept C22070199 @default.
• W2156885603 hasConcept C27081682 @default.

• next